These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27241839)

  • 1. Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.
    Ather S; Shendre A; Beasley TM; Brown T; Hill CE; Prabhu SD; Limdi NA
    Am J Cardiol; 2016 Jul; 118(2):232-6. PubMed ID: 27241839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    McMurray JJ; Ezekowitz JA; Lewis BS; Gersh BJ; van Diepen S; Amerena J; Bartunek J; Commerford P; Oh BH; Harjola VP; Al-Khatib SM; Hanna M; Alexander JH; Lopes RD; Wojdyla DM; Wallentin L; Granger CB;
    Circ Heart Fail; 2013 May; 6(3):451-60. PubMed ID: 23575255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
    Sandhu RK; Hohnloser SH; Pfeffer MA; Yuan F; Hart RG; Yusuf S; Connolly SJ; McAlister FA; Healey JS
    Stroke; 2015 Mar; 46(3):667-72. PubMed ID: 25628308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: a population cohort study.
    Goudie A; Elder D; Deshmukh H; Szwejkowski BR; Lang CC; George J
    Eur J Heart Fail; 2015 Jan; 17(1):90-7. PubMed ID: 25427720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.
    Van Spall HG; Wallentin L; Yusuf S; Eikelboom JW; Nieuwlaat R; Yang S; Kabali C; Reilly PA; Ezekowitz MD; Connolly SJ
    Circulation; 2012 Nov; 126(19):2309-16. PubMed ID: 23027801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
    Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE
    JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.
    Homma S; Thompson JL; Qian M; Ye S; Di Tullio MR; Lip GY; Mann DL; Sacco RL; Levin B; Pullicino PM; Freudenberger RS; Teerlink JR; Graham S; Mohr JP; Labovitz AJ; Buchsbaum R; Estol CJ; Lok DJ; Ponikowski P; Anker SD;
    Circ Heart Fail; 2015 May; 8(3):504-9. PubMed ID: 25850425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center.
    Tseng AS; William Schleifer J; Shen WK; McBane R; Mankad S; Esser H; Vucicevic D; Shamoun FE
    Clin Cardiol; 2017 Dec; 40(12):1328-1332. PubMed ID: 29247519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left Ventricular Ejection Fraction and Clinically Defined Heart Failure to Predict 90-Day Functional Outcome After Ischemic Stroke.
    Li Y; Fitzgibbons TP; McManus DD; Goddeau RP; Silver B; Henninger N
    J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):371-380. PubMed ID: 30396839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and Prognostic Impact of Prophylactic Oral Anticoagulation in Anterior ST-Segment Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction.
    Shavadia JS; Youngson E; Bainey KR; Bakal J; Welsh RC
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation Therapy and NOACs in Heart Failure.
    Thomas I; EncisoSilva J; Schlueter M; Greenberg B
    Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry.
    Wang C; Yang Z; Wang C; Wang Y; Zhao X; Liu L; Wang DZ; Li H; Wang Y
    J Stroke Cerebrovasc Dis; 2014; 23(5):1157-63. PubMed ID: 24291013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
    Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of heart rate recovery in patients with heart failure or left ventricular systolic dysfunction.
    Lipinski MJ; Vetrovec GW; Gorelik D; Froelicher VF
    J Card Fail; 2005 Oct; 11(8):624-30. PubMed ID: 16230267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis: A nationwide population-based study.
    Labaf A; Svensson PJ; Renlund H; Jeppsson A; Själander A
    Am Heart J; 2016 Nov; 181():1-9. PubMed ID: 27823679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.